BiotechTube
Betaliq

Betaliq

San Francisco, United States· Est.
betaliq.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Betaliq is a privately held, clinical-stage biotech focused on developing novel ophthalmic therapies for glaucoma using the exclusive EyeSol® technology. Its lead program, BTQ1902 (a timolol suspension), has completed a positive Phase 2a trial and is preparing for Phase 3. The company operates with a virtual model, is backed by an $8M Series A, and aims to address significant unmet needs in glaucoma care through improved drug delivery.

OphthalmologyGlaucoma

Technology Platform

Exclusive licensee of Novaliq's EyeSol® technology, a water-free drug delivery platform using semifluorinated alkanes. It enhances ophthalmic drug bioavailability by enabling smaller drop size, prolonged ocular surface retention, and preservative-free formulations.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The global glaucoma patient population is projected to exceed 111 million by 2040, representing a large and growing market with unmet needs for better-tolerated and more effective therapies.
Betaliq's EyeSol® platform has been clinically and regulatorily validated in other approved products, de-risking the technology and providing a clear path to differentiate established drugs like timolol.

Risk Factors

Betaliq is a single-asset, pre-revenue company facing significant clinical trial risk as BTQ1902 advances to Phase 3.
It is dependent on its licensed technology from Novaliq and will require substantial additional capital to fund late-stage development in a highly competitive glaucoma market dominated by generics and established brands.

Competitive Landscape

The glaucoma therapeutics market is highly competitive, featuring numerous generic drugs and branded products from major ophthalmology players like Allergan (now AbbVie), Alcon, and Santen. Betaliq's strategy competes by aiming to improve the profile of existing drugs (e.g., timolol) through superior delivery, rather than introducing a novel mechanism, which may face challenges in displacing low-cost generics.

More companies in Drug Delivery & Formulation →More companies in United States →